pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
DUPIXENT · news · pharmadog
← back to DUPIXENT
News mentioning DUPIXENT
73
stories
9h
Sanofi gains FDA clearance for Gaucher disease pill
biopharma dive
11h
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
3d
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
biospace
6d
Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
biospace
14d
STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more
stat
15d
Sanofi stops development of Nurix-partnered immune drug
biopharma dive
15d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
15d
STAT+: Ultragenyx cuts staff after another study fails
stat
15d
STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more
stat
15d
STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug
stat
16d
STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test
stat
16d
STAT+: Who will get the first psychedelic approved?
stat
16d
STAT+: Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more
stat
17d
Washington state resident dies from bird flu following exposure to infected cattle
stat
17d
STAT+: Psilocybin’s lasting benefits prove elusive in mice
stat
17d
STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries
stat
17d
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
stat
17d
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
biopharma dive
17d
Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misled
stat
17d
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
stat
17d
Are you pursuing MRT as a treatment for infertility? Tell us about your experience
stat
20d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
20d
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
biospace
20d
Sanofi has no plans for 'major restructuring' as Dupixent's patent cliff looms
endpoints
20d
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff
fiercebiotech
Oct 12, 26
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
Oct 12, 26
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
biopharma dive
Oct 7, 26
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
Oct 6, 26
The top biopharma conferences in 2027
biopharma dive
Oct 1, 26
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
← prev
page 1 of 3
next →